Drug Design Targeting T-Cell Factor-Driven Epithelial–Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer-Reference-Cited by-同舟云学术

Drug Design Targeting T-Cell Factor-Driven Epithelial–Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer

Published:2019-11-01 Issue:22 Volume:62 Page:10182-10203
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Abraham Adedoyin D.,Esquer Hector,Zhou Qiong,Tomlinson Nicholas,Hamill Brayden D.,Abbott Joshua M.,Li Linfeng,Pike Laura A.,Rinaldetti Sébastien,Ramirez Dominique A.¹,Lunghofer Paul J.¹,Gomez Jose D.,Schaack Jerome,Nemkov Travis,D’Alessandro Angelo^ORCID,Hansen Kirk C.,Gustafson Daniel L.¹,Messersmith Wells A.,LaBarbera Daniel V.^ORCID

Affiliation:

1. Clinical Sciences, School of Biomedical Engineering, Colorado State University, Fort Collins, Colorado 80523, United States

Funder

U.S. Department of Defense

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01065

Reference51 articles.

1. Howlader, N.; Noone, A.; Krapcho, M.; Garshell, J.; Miller, D.; Altekruse, S.; Kosary, C.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.; Chen, H.; Feuer, E.; Cronin, K. e. SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016. ((accessed Nov 7, 2004)).

2. Wnt/β-Catenin Signaling in Development and Disease

3. Comprehensive molecular characterization of human colon and rectal cancer

4. -catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness

5. EMT, cell plasticity and metastasis

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EMT using low-dose Teniposide by downregulating ZEB2-driven activation of RNA polymerase I in breast cancer;Cell Death & Disease;2024-05-08

2. Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review;Cancers;2024-02-06

3. The validation of new CHD1L inhibitors as a therapeutic strategy for cancer;Biomedicine & Pharmacotherapy;2024-01

4. miR-30c-2-3p suppresses the proliferation of human renal cell carcinoma cells by targeting TOP2A;Asian Biomedicine;2023-06-01

5. Tool and Techniques on Computer-Aided Drug Design for Targeted Cancer Therapy;Targeted Cancer Therapy in Biomedical Engineering;2023